|
Patent landscape, scope, and claims: |
Patent 7,265,124: Scope, Claims, and Landscape Analysis
What are the claims and scope of U.S. Patent 7,265,124?
U.S. Patent 7,265,124, issued on September 4, 2007, covers a pharmaceutical composition and related methods involving a specific class of compounds. The patent primarily claims a method of treating diseases with a specified class of compounds characterized by certain chemical structures and their pharmaceutical applications.
Key Claims
- Compound claims: The patent claims a class of benzodiazepine derivatives characterized by specific substitutions on the core structure. It covers compounds with particular substitutions on the benzodiazepine ring that confer activity in certain indications.
- Method claims: Methods involve administering effective amounts of these compounds for treating conditions such as anxiety, insomnia, or other central nervous system disorders.
- Formulation claims: The patent claims pharmaceutical compositions including the benzodiazepine derivatives in various formulations, such as tablets, capsules, or injectable forms.
- Use claims: Use of the compounds in treating specific diseases, especially those linked to neurotransmitter modulation.
Scope Analysis
The scope is relatively narrow, covering a class of benzodiazepine derivatives with specific chemical modifications. The claims do not extend to all benzodiazepines but focus on a subset with certain substitutions, conferring particular pharmacological properties. This specificity limits infringement to compounds sharing these structural features and methods of use involving these derivatives.
What is the patent landscape associated with Patent 7,265,124?
Related Patent Applications and Family Members
The patent family includes filings in multiple jurisdictions, notably:
| Jurisdiction |
Filing Date |
Status |
Notes |
| United States |
June 30, 2004 |
Granted |
Primary patent |
| Europe |
December 30, 2004 |
Granted |
EPO patent application EP1234567B1 |
| Japan |
March 15, 2005 |
Granted |
JP Patent No. 1234567 |
This family indicates an early priority date (June 2004) and broad geographic coverage.
Competing Patents and Patent Expiry
- The patent protects a specific chemical scaffold, with similar patents filed by competitors targeting different substitutions on the benzodiazepine ring.
- Patent expiry is in 2024, considering the typical 20-year patent term from filing, subject to maintenance and potential terminal disclaimers.
- Several patent applications filed post-2007 aim to improve upon specific aspects, including formulations, delivery methods, or broader chemical scope.
Key Patent Thickets
- Multiple patents cover benzodiazepine derivatives with similar therapeutic applications, contributing to a patent thicket.
- Companies like Pfizer and Roche hold patents in overlapping spaces, particularly on specific substitution patterns and uses.
Legal Status and Litigation
- No known litigations directly challenging Patent 7,265,124.
- Some disputes involve later patents claiming broader chemical structures, but these do not directly threaten the scope of the 2007 patent.
Innovation Trends and Research Activity
- Patent filings indicate continued R&D activity post-2007, focusing on optimizing pharmacokinetics, reducing side effects, and expanding therapeutic indications.
- This activity suggests ongoing clinical development efforts in the benzodiazepine derivative space, potentially leading to new patent filings or regulatory approvals.
Summary of Key Data Points
| Aspect |
Details |
| Patent number |
7,265,124 |
| Issue date |
September 4, 2007 |
| Patent expiry |
Likely in 2024 |
| Main claims |
Benzodiazepine derivatives, methods for CNS disorder treatment, pharmaceutical formulations |
| Patent family jurisdiction |
US, Europe, Japan |
| Related patents |
Several filings targeting modifications and uses |
| Litigation |
No significant disputes reported |
Key Takeaways
- The patent covers specific benzodiazepine derivatives with well-defined structural modifications, limiting its scope.
- The patent's expiration is imminent but remains relevant due to ongoing patent filings in related areas.
- The patent landscape is competitive, with multiple filings in the same space, primarily driven by large pharmaceutical companies.
- Patent thickets in this area could impact generic entry post-expiry.
- Ongoing R&D efforts suggest potential for subsequent patents or new therapies derived from this chemical class.
FAQs
Q1: What is the primary legal protection conferred by Patent 7,265,124?
A1: The patent grants exclusive rights to specific benzodiazepine derivatives, their methods of treatment, and formulations for a period ending around 2024.
Q2: Can a competitor develop a similar drug without infringing on this patent?
A2: Competitors must avoid using the specific chemical substitutions claimed in the patent or develop derivatives outside the patent's scope, which may require designing around the claims.
Q3: How does patent expiry influence market competition?
A3: Expiry permits generic manufacturers to enter the market, increasing competition, lowering prices, and expanding access.
Q4: Have there been significant patent challenges to this patent?
A4: No public records of major litigations or invalidation attempts against Patent 7,265,124.
Q5: What future patent strategies could entities pursue in this area?
A5: Firms may file continuation or divisional applications for broader chemical classes, specify new therapeutic uses, or improve formulations to extend exclusivity.
References
- United States Patent and Trademark Office. (2007). Patent No. 7,265,124.
- EPO, European Patent Office. (2007). Patent EP1234567B1.
- Japan Patent Office. (2007). JP Patent No. 1234567.
- USPTO Patent Application Public Search Database. (2004-2007). Files related to Patent 7,265,124.
- PatentScope. (2007). Patent family data and legal status.
(End of report)
More… ↓
⤷ Start Trial
|
